参考文献/References:
[1]Chen W,Zheng R,Baade PD,et al.Cancer statistics in China, 2015[J].CA Cancer J Clin,2016,66(2):115-132. [2]Su D,Singer EA,Srinivasan R.Molecular pathways in renal cell carcinoma: recent advances in genetics and molecular biology[J].Curr Opin Oncol,2015,27(3):217-223.[3]Ljungberg B,Bensalah K,Canfield S,et al.EAU guidelines on renal cell carcinoma: 2014 update[J].Eur Urol,2015,67(5):913-924.[4]Kamal Y,Cheng C,Frost HR,et al.Predictors of disease aggressiveness influence outcome from immunotherapy treatment in renal clear cell carcinoma[J].Oncoimmunology,2018,8(1):e1500106.[5]Xu J,Li N,Deng W,et al.Discovering the mechanism and involvement of the methylation of cyclin-dependent kinase inhibitor 2A (CDKN2A) gene and its special locus region in gastric cancer[J].Bioengineered,2021,12(1):1286-1298.[6]Hayashi T,Shibata T,Nakamura M,et al.MAFK Polymorphisms Located in 3’-UTR are Associated with Severity of Atrophy and CDKN2A Methylation Status in the Gastric Mucosa[J].Genet Test Mol Biomarkers,2021,25(4):255-262. [7]Wang L,Xu L,Wang Y.Huaier Inhibits Proliferation, Migration, and Invasion of Cutaneous Squamous Cell Carcinoma Cells by Inhibiting the Methylation Levels of CDKN2A and TP53[J].Integr Cancer Ther,2021,20:15347354211031646.[8]Sumida K,Han Z,Dashputre AA,et al.Association between Nrf2 and CDKN2A expression in patients with end-stage renal disease: a pilot study[J].Aging (Albany NY),2020,12(16):16357-16367.[9]Bartels S,van Luttikhuizen JL,Christgen M,et al.CDKN2A loss and PIK3CA mutation in myoepithelial-like metaplastic breast cancer[J].J Pathol,2018,245(3):373-383.[10]Fraz?觔o L,do Carmo Martins M,Nunes VM,et al.BRAF V600E mutation and 9p21: CDKN2A/B and MTAP co-deletions-Markers in the clinical stratification of pediatric gliomas[J].BMC Cancer,2018,18(1):1259.[11]Gironi LC,Colombo E,Pasini B,et al.Melanoma-prone families: new evidence of distinctive clinical and histological features of melanomas in CDKN2A mutation carriers[J].Arch Dermatol Res,2018,310(10):769-784.[12]Ibrahim I,Sibinga Mulder BG,Bonsing B,et al.Risk of multiple pancreatic cancers in CDKN2A-p16-Leiden mutation carriers[J].Eur J Hum Genet,2018,26(8):1227-1229.[13]Thompson ED,Roberts NJ,Wood LD,et al.The genetics of ductal adenocarcinoma of the pancreas in the year 2020: dramatic progress, but far to go[J].Mod Pathol,2020,33(12):2544-2563.[14]Ibrahim IS,Wasser MN,Wu Y,et al.High Growth Rate of Pancreatic Ductal Adenocarcinoma in CDKN2A-p16-Leiden Mutation Carriers[J].Cancer Prev Res (Phila),2018,11(9):551-556.[15]Potjer TP,van der Stoep N,Houwing-Duistermaat JJ,et al.Pancreatic cancer-associated gene polymorphisms in a nation-wide cohort of p16-Leiden germline mutation carriers; a case-control study[J].BMC Res Notes,2015,8:264. [16]Yang C,Cimera RS,Aryeequaye R,et al.Adverse histology, homozygous loss of CDKN2A/B, and complex genomic alterations in locally advanced/metastatic renal mucinous tubular and spindle cell carcinoma[J].Mod Pathol,2021,34(2):445-456. [17]McClure JJ,Li X,Chou CJ.Advances and Challenges of HDAC Inhibitors in Cancer Therapeutics[J].Adv Cancer Res,2018,138:183-211. [18]Ke X,Qin Q,Deng T,et al.Heterogeneous Responses of Gastric Cancer Cell Lines to Tenovin-6 and Synergistic Effect with Chloroquine[J].Cancers (Basel),2020,12(2):365. [19]Aftab A,Shahzad S,Hussain HMJ,et al.CDKN2A/P16INK4A variants association with breast cancer and their in-silico analysis[J].Breast Cancer,2019,26(1):11-28.[20]Sun Q,Chen S,Hou Y,et al.Mutant CDKN2A regulates P16/p14 expression by alternative splicing in renal cell carcinoma metastasis[J].Pathol Res Pract,2021,223:153453.
相似文献/References:
[1]桂慧慧,刘 霞.基于多数据库分析MYH10在肾透明细胞癌中的表达与意义[J].医学信息,2022,35(10):20.[doi:10.3969/j.issn.1006-1959.2022.10.004]
GUI Hui-hui,LIU Xia.Expression and Significance of MYH10 in Renal Clear Cell Carcinoma Based on Multi-database Analysis[J].Journal of Medical Information,2022,35(16):20.[doi:10.3969/j.issn.1006-1959.2022.10.004]
[2]毛 伟,张 琳,刘清钊.肾透明细胞癌细胞焦亡相关基因预后模型的建立与应用[J].医学信息,2022,35(14):1.[doi:10.3969/j.issn.1006-1959.2022.14.001]
MAO Wei,ZHANG Lin,LIU Qing-zhao.Constructionand Application of Pyroptosis-related Genes Prognosis Model in Clear Cell Renal Cell Carcinoma[J].Journal of Medical Information,2022,35(16):1.[doi:10.3969/j.issn.1006-1959.2022.14.001]
[3]唐怀慧,王忠帅,邵茜茜,等.基于TCGA数据库肺腺癌RNAs构建ceRNA网络的综合分析[J].医学信息,2020,33(07):90.[doi:10.3969/j.issn.1006-1959.2020.07.025]
TANG Huai-hui,WANG Zhong-shuai,SHAO Qian-qian,et al.Comprehensive Analysis of Constructing ceRNA Network Based on TCGA Database of Lung Adenocarcinoma RNAs[J].Journal of Medical Information,2020,33(16):90.[doi:10.3969/j.issn.1006-1959.2020.07.025]
[4]李前进,拜合提亚·阿扎提,王文光,等.ST6GalⅠ在肾透明细胞癌中表达及其与病理特征的关系[J].医学信息,2021,34(06):87.[doi:10.3969/j.issn.1006-1959.2021.06.022]
LI Qian-jin,Baihetia Azati,WANG Wen-guang,et al.The Expression of ST6GalⅠ in Renal Clear Cell Carcinoma and Its Relationship with Pathological Features[J].Journal of Medical Information,2021,34(16):87.[doi:10.3969/j.issn.1006-1959.2021.06.022]
[5]吴文杰,裴天龙,汪永康,等.基于CT影像组学特征预测肾透明细胞癌分化程度的研究[J].医学信息,2021,34(11):96.[doi:10.3969/j.issn.1006-1959.2021.11.026]
WU Wen-jie,PEI Tian-long,WANG Yong-kang,et al.Study on Predicting Differentiation Degree of Renal Clear Cell Carcinoma Based on CT Imaging Features[J].Journal of Medical Information,2021,34(16):96.[doi:10.3969/j.issn.1006-1959.2021.11.026]
[6]单 丽,朱晓力,向程程,等.基于NUF2mRNA、HAMP mRNA、分期、病理分级及年龄的预后评估模型在肾透明细胞癌预后判断中的运用[J].医学信息,2023,36(09):42.[doi:10.3969/j.issn.1006-1959.2023.09.007]
SHAN Li,ZHU Xiao-li,XIANG Cheng-cheng,et al.The Application of Prognostic Evaluation Model Based on NUF2mRNA,HAMP mRNA,Stage,Pathological Grade and Age in the Prognosis of Kidney Renal Clear Cell Carcinoma[J].Journal of Medical Information,2023,36(16):42.[doi:10.3969/j.issn.1006-1959.2023.09.007]
[7]林思其,张泽鑫,夏睿琪,等.三种miRNA对肝癌预后预测的生物信息学分析模型[J].医学信息,2022,35(03):81.[doi:10.3969/j.issn.1006-1959.2022.03.019]
LIN Si-qi,ZHANG Ze-xin,XIA Rui-qi,et al.A Model of Three miRNA on the Prognosis Prediction of Hepatocellular Carcinomaby Bioinformatics Analysis[J].Journal of Medical Information,2022,35(16):81.[doi:10.3969/j.issn.1006-1959.2022.03.019]